Trial Profile
A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Avadomide (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celgene Corporation
- 06 Sep 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2023 Planned End Date changed from 20 Feb 2023 to 9 May 2023.
- 20 Apr 2023 Planned primary completion date changed from 20 Feb 2023 to 9 May 2023.